Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:clinical_trial |
Phase 2
|
| gptkbp:dlc |
0049-0123
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:has_ability |
100 mg
|
| https://www.w3.org/2000/01/rdf-schema#label |
Lorbrena
|
| gptkbp:ingredients |
gptkb:lorlatinib
|
| gptkbp:interacts_with |
strong CY P3 A inducers
strong CY P3 A inhibitors |
| gptkbp:is_atype_of |
L01 X E34
|
| gptkbp:is_used_for |
treatment of non-small cell lung cancer
|
| gptkbp:manager |
oral
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:marketed_as |
gptkb:2018
|
| gptkbp:monitors |
3 B1 B1 D1 F1 D
|
| gptkbp:packaging |
gptkb:beer
|
| gptkbp:side_effect |
fatigue
nausea diarrhea peripheral neuropathy elevated liver enzymes |
| gptkbp:social_structure |
C21 H24 Cl N5 O2 S
|
| gptkbp:storage |
store at room temperature
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
| gptkbp:bfsLayer |
5
|